Orforglipron
Orforglipron (LY3502970) is an oral non-peptide small molecule GLP-1 receptor agonist developed by Eli Lilly. It is the first oral non-peptide GLP-1 agonist to reach Phase 3 clinical trials, offering once-daily dosing without fasting requirements and demonstrating significant weight loss and glycemic improvement.
Orforglipron (LY3502970) is a novel oral non-peptide small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. Unlike injectable GLP-1 receptor agonists such as semaglutide or liraglutide, and unlike oral semaglutide which is still a peptide requiring a permeation enhancer and fasting conditions, orforglipron is a fully synthetic small molecule that can be taken orally once daily with or without food.
Overview
Orforglipron was discovered through medicinal chemistry optimization of a non-peptide GLP-1 receptor agonist scaffold. As a small molecule rather than a peptide, it is not degraded by gastrointestinal proteases and does not require the specialized absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) that oral semaglutide (Rybelsus) depends on. This means orforglipron can be taken without fasting requirements, with any amount of water, and without the 30-minute post-dose food restriction that limits oral semaglutide's practicality.
Eli Lilly's ACHIEVE clinical trial program is evaluating orforglipron across multiple Phase 3 studies in type 2 diabetes and obesity. The compound has demonstrated clinically meaningful weight loss and HbA1c reductions in Phase 2 trials, positioning it as a potential first-in-class oral non-peptide GLP-1 agonist for metabolic diseases. If approved, orforglipron could dramatically expand access to GLP-1 receptor agonist therapy, as oral small molecules are easier and cheaper to manufacture at scale than peptide-based biologics.
Mechanism of Action
Orforglipron activates the GLP-1 receptor through a distinct binding mode compared to peptide GLP-1 agonists, but produces overlapping downstream signaling:
GLP-1 Receptor Full Agonism: Orforglipron binds to the GLP-1 receptor at an allosteric/orthosteric hybrid site distinct from the peptide-binding groove. Despite its different binding orientation, it functions as a full agonist, activating Gs-coupled cAMP signaling with potency comparable to native GLP-1. This drives glucose-dependent insulin secretion from pancreatic beta cells.
Biased Agonism Profile: Preclinical data suggest orforglipron may exhibit a partially biased signaling profile relative to native GLP-1, with robust cAMP generation but potentially different beta-arrestin recruitment patterns. This biased agonism may contribute to its distinct tolerability profile and sustained receptor signaling.
Appetite Suppression: Like peptide GLP-1 agonists, orforglipron crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem appetite centers, reducing hunger and caloric intake. Central GLP-1R activation in the nucleus tractus solitarius and area postrema contributes to satiety signaling.
Gastric Emptying Delay: Orforglipron slows gastric emptying through vagal afferent signaling, contributing to postprandial glucose control and enhanced satiety. This mechanism is shared with all GLP-1R agonists.
Glucagon Suppression: Activation of GLP-1 receptors suppresses inappropriate glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output, particularly in the postprandial state.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Comparison with Oral Semaglutide
Orforglipron offers several practical advantages over oral semaglutide (Rybelsus). Oral semaglutide requires ingestion on an empty stomach with no more than 4 oz of water, followed by a 30-minute fast, and has a bioavailability of only 0.4-1%. Orforglipron, as a small molecule, does not require fasting, can be taken with food or water, and has substantially higher oral bioavailability. This eliminates one of the major compliance barriers associated with oral semaglutide and may result in more consistent drug exposure across patients.
Metabolic Parameters
Beyond weight loss and glycemic control, Phase 2 data showed orforglipron improved multiple cardiometabolic risk factors. Significant reductions were observed in waist circumference, fasting triglycerides, total cholesterol, and markers of systemic inflammation. These pleiotropic metabolic benefits are consistent with the broader cardiometabolic effects observed with injectable GLP-1R agonists and support investigation of cardiovascular outcomes.
Manufacturing and Access Advantages
As a small molecule, orforglipron can be manufactured through conventional chemical synthesis rather than the recombinant DNA technology or solid-phase peptide synthesis required for peptide and protein GLP-1 agonists. This has implications for manufacturing scalability, cold-chain requirements (orforglipron is stable at room temperature), and ultimately cost. These advantages could address the supply constraints and high costs that have limited access to current GLP-1R agonist therapies globally.
Weight Loss
The Phase 2 dose-ranging trial of orforglipron in adults with obesity or overweight demonstrated substantial weight loss across multiple dose levels over 36 weeks. Participants receiving the highest evaluated dose (45 mg daily) achieved a mean body weight reduction of 14.7% from baseline, compared to 2.3% with placebo. Weight loss was progressive and had not plateaued at 36 weeks, suggesting further reductions might occur with extended treatment. The dose-response relationship was clear, with 12 mg, 24 mg, 36 mg, and 45 mg doses producing 8.6%, 12.6%, 12.4%, and 14.7% weight loss respectively. Frias et al. (2023) — N. Engl. J. Med.
Type 2 Diabetes
In a Phase 2 trial in patients with type 2 diabetes, orforglipron demonstrated significant HbA1c reductions across dose levels over 26 weeks. The 45 mg dose achieved a mean HbA1c reduction of 2.1 percentage points from a baseline of approximately 8.0%, bringing most patients to target glycemic levels. Fasting plasma glucose reductions were also clinically meaningful. These results compare favorably with injectable GLP-1 receptor agonists in similar populations. Frias et al. (2023) — N. Engl. J. Med.
Safety Profile
In Phase 2 trials, the most common adverse events with orforglipron were gastrointestinal in nature, consistent with GLP-1R agonist pharmacology. Nausea occurred in 33-49% of participants (dose-dependent), vomiting in 7-21%, diarrhea in 15-22%, and constipation in 7-11%. Most GI events were mild to moderate in severity and occurred primarily during dose escalation. Discontinuation rates due to adverse events ranged from 10-17% across dose groups compared to 3-5% for placebo. No cases of pancreatitis were reported in Phase 2 trials. Dose-dependent increases in heart rate of 4-8 bpm were observed, consistent with other GLP-1R agonists. No thyroid C-cell signals have been detected in clinical studies to date, though long-term monitoring is ongoing.
Pharmacokinetic Profile
Orforglipron — Pharmacokinetic Curve
Oral (once daily)Ongoing & Future Research
- ACHIEVE Phase 3 program: Multiple registrational trials ongoing across type 2 diabetes and obesity indications, with results expected 2025-2026.
- Cardiovascular outcomes: ACHIEVE-4 trial enrolling patients with established cardiovascular disease or high cardiovascular risk to evaluate MACE reduction.
- MASH/NASH: Potential future studies leveraging the hepatic fat reduction observed with GLP-1R agonists.
- Combination with tirzepatide components: Eli Lilly exploring whether oral non-peptide GIP agonists could be combined with orforglipron for an oral dual incretin approach.
- Pediatric/adolescent obesity: Future studies anticipated given regulatory interest in expanding weight management options for younger populations.
- Renal outcomes: Potential dedicated renal outcome trials based on the class effect of GLP-1R agonists on kidney function.
Quick Start
- Typical Dose
- Start 3-6mg daily, titrate up to 12-36mg based on response
- Frequency
- Once daily oral tablet
- Route
- Oral (once daily)
- Cycle Length
- Long-term continuous therapy (72+ weeks in trials)
- Storage
- Room temperature 15-30°C; no refrigeration needed
Molecular Structure
- Formula
- C30H31F2N3O4
- Weight
- 882.974 Da
- CAS
- 2172752-65-7
- PubChem CID
- 163428783
- Exact Mass
- 629.3077 Da
- LogP
- 4.7
- TPSA
- 99.2 Ų
- H-Bond Donors
- 2
- H-Bond Acceptors
- 9
- Rotatable Bonds
- 13
- Complexity
- 1110
Identifiers (SMILES, InChI)
InChI=1S/C34H42F3N3O5/c1-21(2)16-28(40-20-25(14-15-39(5)6)27(18-29(40)41)34(35,36)37)32(43)38-33(44,19-30(42)45-7)26-13-9-12-24(17-26)31-22(3)10-8-11-23(31)4/h8-13,17-18,20-21,28,44H,14-16,19H2,1-7H3,(H,38,43)/t28?,33-/m0/s1
AOSRIAMQZLOPKZ-OVUYURIWSA-NResearch Indications
Weight Loss
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
Type 2 Diabetes
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Research Protocols
oral
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Type 2 diabetes initiation | 3mg daily | Once daily, any time | —(Route: Oral tablet) |
| Type 2 diabetes moderate control | 12mg daily | Once daily, any time | —(Route: Oral tablet) |
| Type 2 diabetes optimal control | 36mg daily | Once daily, any time | —(Route: Oral tablet) |
| Weight loss initiation | 6mg daily | Once daily, any time | —(Route: Oral tablet) |
| Weight loss optimization | 36mg daily | Once daily, any time | —(Route: Oral tablet) |
Interactions
Peptide Interactions
- Combination with tirzepatide components: Eli Lilly exploring whether oral non-peptide GIP agonists could be combined with orforglipron for an oral dual incretin approach.
Orforglipron offers several practical advantages over oral semaglutide (Rybelsus). Oral semaglutide requires ingestion on an empty stomach with no more than 4 oz of water, followed by a 30-minute fast, and has a bioavailability of only 0.4-1%. Orforglipron, as a small molecule, does not require f...
What to Expect
What to Expect
Appetite reduction typically within 1-3 days; mild to moderate nausea common
Gradual weight loss begins (0.5-2 lbs per week); improved blood sugar control
Reduced food cravings; GI adverse effects generally diminish; metabolic markers improving
Continued progressive weight loss without plateau
Long-term therapy well-tolerated; sustained benefits at 72 weeks
Safety Profile
Common Side Effects
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Discontinue If
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
Quality Indicators
What to look for
- Intact tablet packaging with proper labeling, batch numbers, and expiration dates
- Uniform tablet appearance without discoloration, chipping, or cracking
- Proper storage at room temperature (15-30°C)
Caution
- As of late 2025, orforglipron remains investigational only; any product claiming FDA approval is fraudulent
Red flags
- Discolored, crumbling, or damaged tablets indicate improper storage
- Moisture exposure or humidity damage
Frequently Asked Questions
References (12)
- [2]
- [8]
- [9]Frias, J. P. et al Efficacy and safety of oral orforglipron in patients with type 2 diabetes Lancet (2023)
- [10]Saxena, A. R. et al LY3502970, a novel oral non-peptide GLP-1 receptor agonist Diabetes Obes. Metab. (2023)
- [1]ATTAIN-1 Phase 3 Trial (Obesity) (2025)
- [3]ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes) (2025)
- [4]Phase 2 Obesity Study (2023)
- [5]ATTAIN-2 Phase 3 Trial (Obesity + T2DM) (2025)
- [7]Phase 1 Safety and Pharmacokinetics Studies (2023)
- [6]
- [11]
- [12]Zhao, F. et al — Non-peptide GLP-1 receptor agonists: advances and challenges in oral treatment of type 2 diabetes Eur. J. Med. Chem. (2024)
Oligopeptide-68
Oligopeptide-68 (B-White) is a tyrosinase inhibitor peptide that blocks melanin biosynthesis by reducing MITF expression, used in skin brightening and hyperpigmentation treatment.
Osteopontin-Derived Peptides
Osteopontin-derived peptides, including the thrombin-cleaved SVVYGLR fragment and RGD-containing sequences, are bioactive fragments of the extracellular matrix protein osteopontin (OPN). These peptides mediate angiogenesis, integrin-dependent cell adhesion, immune cell recruitment, and bone remodeling through distinct receptor interactions.